| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Arbutus Biopharma Corporation (NASDAQ: ABUS)
ABUS Technical Analysis
4
| As on 9th Jun 2023 ABUS SHARE Price closed @ 2.48 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.66 & Strong Sell for SHORT-TERM with Stoploss of 3.25 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ABUSSHARE Price
| Open | 2.53 | Change | Price | % |
| High | 2.56 | 1 Day | -0.06 | -2.36 |
| Low | 2.48 | 1 Week | -0.01 | -0.40 |
| Close | 2.48 | 1 Month | -0.03 | -1.20 |
| Volume | 484200 | 1 Year | -1.81 | -42.19 |
| 52 Week High 4.38 | 52 Week Low 1.88 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ABUS Daily Charts |
ABUS Intraday Charts |
Whats New @ Bazaartrend |
ABUS Free Analysis |
|
|
ABUS Important Levels Intraday
| RESISTANCE | 2.63 |
| RESISTANCE | 2.58 |
| RESISTANCE | 2.55 |
| RESISTANCE | 2.52 |
| SUPPORT | 2.44 |
| SUPPORT | 2.41 |
| SUPPORT | 2.38 |
| SUPPORT | 2.33 |
ABUS Forecast April 2024
| 4th UP Forecast | 4.87 |
| 3rd UP Forecast | 4.1 |
| 2nd UP Forecast | 3.63 |
| 1st UP Forecast | 3.16 |
| 1st DOWN Forecast | 1.8 |
| 2nd DOWN Forecast | 1.33 |
| 3rd DOWN Forecast | 0.86 |
| 4th DOWN Forecast | 0.09 |
ABUS Weekly Forecast
| 4th UP Forecast | 3.46 |
| 3rd UP Forecast | 3.15 |
| 2nd UP Forecast | 2.95 |
| 1st UP Forecast | 2.76 |
| 1st DOWN Forecast | 2.20 |
| 2nd DOWN Forecast | 2.01 |
| 3rd DOWN Forecast | 1.81 |
| 4th DOWN Forecast | 1.50 |
ABUS Forecast2024
| 4th UP Forecast | 7.26 |
| 3rd UP Forecast | 5.73 |
| 2nd UP Forecast | 4.78 |
| 1st UP Forecast | 3.83 |
| 1st DOWN Forecast | 1.13 |
| 2nd DOWN Forecast | 0.18 |
| 3rd DOWN Forecast | -0.77 |
| 4th DOWN Forecast | -2.3 |
Arbutus Biopharma Corporation ( NASDAQ USA Symbol : ABUS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ABUS Business Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical trial collaboration agreement with Vaccitech plc to evaluate a therapeutic combination for the treatment of subjects with chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Address: 701 Veterans Circle, Warminster, PA, United States, 18974
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service